Side-by-side comparison of AI visibility scores, market position, and capabilities
Tortus AI provides an AI agent that sits alongside clinicians during patient visits, automatically generating clinical notes and handling documentation tasks in real time.
Tortus AI is a healthcare AI company founded in 2022 in London that develops an AI agent designed to reduce the documentation burden on physicians and clinical staff. The platform operates as a persistent AI presence during clinical encounters, listening to patient-clinician conversations and automatically generating structured clinical notes, coding suggestions, referral letters, and other administrative documentation. Unlike simple transcription tools, Tortus AI interprets clinical context to generate documentation that conforms to specialty-specific formats and coding requirements. The company serves NHS trusts and private healthcare organizations in the United Kingdom and is expanding internationally. Physician burnout driven by excessive documentation requirements is a critical healthcare workforce crisis, with doctors spending roughly half their working time on administrative tasks rather than patient care. Tortus AI addresses this directly by taking over documentation workflows and allowing clinicians to focus on clinical reasoning and patient relationships. The company raised $12M and has deployed across multiple clinical specialties including primary care, emergency medicine, and outpatient specialties with strong clinician satisfaction rates.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.